Comparison of 2-year clinical outcomes with sirolimus and paclitaxel-eluting stents for patients with diabetes: results of the Registro Regionale Angioplastiche Emilia-Romagna Registry.


Department of Cardiology, S. Maria delle Croci Hospital, Azienda Unità Sanitaria Locale Ravenna, Viale Randi 5, Ravenna 48100, Italy. balducelli@libero.it

Comment in:
Catheterization and Cardiovascular Interventions. 2010 Feb 15; 75(3): 335-337.

Abstract

BACKGROUND: Long-term outcomes of percutaneous coronary interventions (PCI) with sirolimus-eluting stents (SES) compared to paclitaxel-eluting-stents (PES) in unselected diabetics in routine practice is still debated.

OBJECTIVE: This study compared the 2-year incidence of MACE (all-cause mortality, nonfatal myocardial infarction and target vessel revascularization) of SES and PES in a real-world setting of patients with diabetes.

DESIGN: Observational, multicenter, nonrandomized study.

SETTING: Prospective web-based registry (REAL Registry; study period, 2002-2005) comprising all 13 hospitals performing PCI.

PATIENTS: Among the 945 eligible patients treated with either SES alone (n = 606) or PES alone (n = 339), 29% were insulin-requiring, 72% had multivessel coronary disease, 26% had prior myocardial infarction and 10% had poor left ventricular function.

MEASUREMENTS: Unadjusted and propensity score-adjusted 2-year clinical outcome.

RESULTS: After propensity score adjustment, 2-year MACE incidence in the SES and PES groups was equivalent (23.3% vs. 23.7%, HR 1.01, 95%CI 0.72-1.42, P = 0.96). Adjusted 2-year angiographic stent thrombosis occurred in 1.1% of the SES patients versus 2.6% of the PES patients (P = 0.15). In this large, real-world, diabetic population treated with DES, there was no difference in outcome between SES and
PES. Further studies are needed to demonstrate the long-term safety of different types of DES in patients with diabetes